Yungjin Pharm Co Ltd - Asset Resilience Ratio
Yungjin Pharm Co Ltd (003520) has an Asset Resilience Ratio of 4.23% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Yungjin Pharm Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Yungjin Pharm Co Ltd's Asset Resilience Ratio has changed over time. See Yungjin Pharm Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Yungjin Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Yungjin Pharm Co Ltd (003520) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩10.00 Billion | 4.23% |
| Total Liquid Assets | ₩10.00 Billion | 4.23% |
Asset Resilience Insights
- Limited Liquidity: Yungjin Pharm Co Ltd maintains only 4.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yungjin Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Yungjin Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277 |
Drug Manufacturers - Specialty & Generic | 31.63% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 3.29% |
Annual Asset Resilience Ratio for Yungjin Pharm Co Ltd (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Yungjin Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 1.32% | ₩3.00 Billion ≈ $2.03 Million |
₩226.60 Billion ≈ $153.56 Million |
-2.60pp |
| 2017-12-31 | 3.92% | ₩8.00 Billion ≈ $5.42 Million |
₩203.85 Billion ≈ $138.14 Million |
+3.80pp |
| 2016-12-31 | 0.12% | ₩240.00 Million ≈ $162.64K |
₩199.35 Billion ≈ $135.10 Million |
-0.67pp |
| 2014-12-31 | 0.79% | ₩1.41 Billion ≈ $955.54K |
₩178.97 Billion ≈ $121.28 Million |
-- |
About Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The com… Read more